The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.
Researchers identified an immune signature in stage II colon cancer that predicts worse outcomes, offering a path to identify patients who might benefit from intensified treatment.
This prospective clinical-trial correlative transcriptomic study examined The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study. In this study, whole-transcriptome profiling of high-risk stage II CRC from the prospective TOSCA trial identified an Immune Exclusion (IE) signature associated with significantly shorter disease-free survival, which remained associated with DFS after adjustment for MSI status and tumor sidedness.
What the study was
- Study design
- Prospective clinical-trial correlative transcriptomic study
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Translational oncology
Why it surfaced
Abstract-backed prospective clinical-trial correlative transcriptomic study relevant to Precision oncology and genomic medicine; scored conservatively because full text was not assessed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.